Izett Matthew, Zacche Martino, Thiagamoorthy Ganesh, Robinson Dudley, Cardozo Linda
Department of Urogynecology, King's College Hospital NHS Foundation Trust, London, UK.
Department of Urogynecology, King's College Hospital NHS Foundation Trust, London, UK -
Minerva Ginecol. 2017 Jun;69(3):269-285. doi: 10.23736/S0026-4784.17.04043-6. Epub 2017 Mar 14.
Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician's armamentarium for refractory cases. Despite these therapeutic options many patients find therapies ineffective or have adverse events. This has resulted in ongoing developments in the understanding of overactive bladder, potential new drugs and combination therapies, which this paper intends to review.
膀胱过度活动症是一种常见的症状复合体，对个人的健康相关生活质量以及卫生资源利用都会产生影响。抗毒蕈碱疗法一直是主要的治疗方法，并且在文献和指南中得到了充分支持。然而，由于疗效不佳和不良事件，导致新疗法的出现，患者的依从性较差。米拉贝隆，一种β3肾上腺素能受体激动剂，已成为基于证据的一线或二线替代疗法。在首次临床应用于膀胱过度活动症二十年后，膀胱内注射肉毒杆菌毒素现在已成为任何临床医生治疗难治性病例的重要手段。尽管有这些治疗选择，但许多患者发现这些疗法无效或出现不良事件。这导致了对膀胱过度活动症的认识、潜在新药和联合疗法的不断发展，本文旨在对此进行综述。
